<DOC>
	<DOCNO>NCT02577458</DOCNO>
	<brief_summary>This Phase I Dose-Escalation Study Evaluate Safety , Tolerability , Pharmacokinetics , Preliminary Efficacy CM082 Combination Everolimus Chinese Patients With Advanced Renal Cell Carcinoma .</brief_summary>
	<brief_title>Study Combination CM082 With Everolimus Patients With mRCC</brief_title>
	<detailed_description>This Phase I Dose-Escalation Study Evaluate Safety , Tolerability , Pharmacokinetics , Preliminary Efficacy CM082 Combination Everolimus Chinese Patients With Renal Cell Carcinoma ( RCC ) . After maximum tolerate dose ( MTD ) optimal biological dose identify , expansion cohort ~10 advance renal cell carcinoma patient enrol characterize safety tumor response CT .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis clear cell renal cell carcinoma Progressed least one standard therapy Measurable disease per Recist1.1 Eastern Cooperative Group ( ECOG ) Performance Status score 0 1 Life expectancy least 12 week No abnormal bone marrow function Adequate heart , lung , liver , kidney organ system function , meet following requirement : Total bilirubin ≤1.5 time upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤1.5x upper limit normal ( ULN ) liver involvement ≤5x upper limit normal liver involvement . Creatinine ≤ 1.5 x ULN Urine protein &lt; 1+ QTcF &lt; 450 m LVEF ≥ 50 % At least 4 week receive cancer therapy ( i.e. , chemotherapy , radiation therapy , biologic therapy , hormonal therapy ) ; 3 month surgery recover Willingness ability comply trial followup procedure Ability understand nature trial give write informed consent Currently receive anticancer treatment Other tumor addition renal cell carcinoma Have take strong cytochrome P450 3A4 inhibitor inducer last 2 week Concomitant use drug risk cause prolong correct QT interval and/or Torsades de Pointes Patients history intolerance , significant toxicity VEGFR tyrosine kinase inhibitor ( ) ( TKI ) everolimus Females pregnant breastfeed Those reproductive age refuse use contraception Those concurrent condition ( e.g . psychological , neuronal , cardiovascular , respiratory condition infection ) investigator 's opinion would jeopardize compliance protocol Patients known central nervous system ( CNS ) metastases Presence active gastrointestinal ( GI ) disease condition interfere significantly absorption , distribution , metabolism , excretion CM082 everolimus Patients know severe lung disorder asthma , chronic obstructive pulmonary disease ( COPD ) Patients HIV positive Drug alcohol abuser</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>